Boehringer Ingelheim exits Hikma Pharmaceuticals

By Aidan Gregory
23 Jun 2020

German pharmaceuticals company Boehringer Ingelheim has sold its remaining stake in UK drug maker Hikma Pharmaceuticals, after a surge in investor interest in pharma stocks during the Covid-19 global pandemic.

JP Morgan and Citigroup were bookrunners. Rothschild was financial adviser to Boehringer Ingelheim.

The placing consisted of 27.2m shares, an 11.5% stake in Hikma. At the 2300p final offer price, the sale priced at a 7.2% discount to the closing price of the stock on ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial